| 1 | Noonan syndrome and noonan-related syndrome | Enrichment | MAP2K1, MAP2K2, PTPN11, RAF1 | 6.60 |
| 2 | Breast adenocarcinoma | Enrichment | AKT1, PIK3CA, TP53 | 5.98 |
| 3 | Noonan syndrome 1 | Enrichment | MAP2K1, MAP2K2, PTPN11, RAF1 | 5.79 |
| 4 | Rasopathy | Enrichment | MAP2K1, MAP2K2, PTPN11, RAF1 | 5.57 |
| 5 | Cardiofaciocutaneous syndrome 1 | Enrichment | MAP2K1, MAP2K2 | 4.07 |
| 6 | Cardiofaciocutaneous syndrome | Enrichment | MAP2K1, MAP2K2 | 4.07 |
| 7 | Noonan syndrome with multiple lentigines | Enrichment | PTPN11, RAF1 | 4.07 |
| 8 | Cerebral malaria | Enrichment | ICAM1, TNF | 4.07 |
| 9 | Lymphoma | Enrichment | PTPN11, TP53 | 3.84 |
| 10 | Breast cancer | Enrichment | AKT1, JUN, PIK3CA, TP53 | 3.72 |
| 11 | Hemihyperplasia, isolated | Enrichment | PIK3CA, RHOA | 3.67 |
| 12 | Capillary malformation-arteriovenous malformation 1 | Enrichment | MAP2K1, PIK3CA | 3.52 |
| 13 | Noonan syndrome 3 | Enrichment | PTPN11, RAF1 | 3.52 |
| 14 | Gallbladder cancer | Enrichment | PIK3CA, TP53 | 3.52 |
| 15 | Colorectal cancer | Enrichment | AKT1, PIK3CA, SRC, TP53 | 3.47 |
| 16 | Arteriovenous malformation | Enrichment | MAP2K1, PIK3CA | 3.29 |
| 17 | Adult hepatocellular carcinoma | Enrichment | PIK3CA, TP53 | 3.29 |
| 18 | Cowden syndrome | Enrichment | AKT1, PIK3CA | 3.29 |
| 19 | Hereditary breast carcinoma | Enrichment | AKT1, PIK3CA, TP53 | 3.20 |
| 20 | Myopathy, x-linked, with excessive autophagy | Enrichment | MAP2K1, PIK3CA | 3.20 |
| 21 | Lung non-small cell carcinoma | Enrichment | MAP2K1, PIK3CA | 3.11 |
| 22 | Specific learning disability | Enrichment | MAPK1, PTPN11 | 3.11 |
| 23 | Meningioma | Enrichment | AKT1, PIK3CA | 3.03 |
| 24 | Lip and oral cavity carcinoma | Enrichment | PIK3CA, TP53 | 3.03 |
| 25 | Osteoporosis | Enrichment | COL1A1, SRC | 2.89 |
| 26 | Human immunodeficiency virus type 1 | Enrichment | CCL2, IL10 | 2.67 |
| 27 | Hepatocellular carcinoma | Enrichment | PIK3CA, TP53 | 2.50 |
| 28 | Brittle bone disorder | Enrichment | ALPL, COL1A1 | 2.46 |
| 29 | Malaria | Enrichment | ICAM1, TNF | 2.46 |
| 30 | Scoliosis | Enrichment | MYF5, PTPN11 | 2.42 |
| 31 | Macrodactyly | Enrichment | PIK3CA | 2.42 |
| 32 | Proteus syndrome | Enrichment | AKT1 | 2.42 |
| 33 | Metachondromatosis | Enrichment | PTPN11 | 2.42 |
| 34 | Noonan syndrome 5 | Enrichment | RAF1 | 2.42 |
| 35 | Hypophosphatasia, adult | Enrichment | ALPL | 2.42 |
| 36 | Melorheostosis, isolated | Enrichment | MAP2K1 | 2.42 |
| 37 | Megalencephaly, autosomal dominant | Enrichment | PIK3CA | 2.42 |
| 38 | Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or impaired intellectual development | Enrichment | YAP1 | 2.42 |
| 39 | Leopard syndrome 1 | Enrichment | PTPN11 | 2.42 |
| 40 | Cardiomyopathy, dilated, 1nn | Enrichment | RAF1 | 2.42 |
| 41 | Cowden syndrome 5 | Enrichment | PIK3CA | 2.42 |
| 42 | Cardiofaciocutaneous syndrome 3 | Enrichment | MAP2K1 | 2.42 |
| 43 | Hypophosphatasia, childhood | Enrichment | ALPL | 2.42 |
| 44 | Cerebral cavernous malformations 4 | Enrichment | PIK3CA | 2.42 |
| 45 | Noonan syndrome 13 | Enrichment | MAPK1 | 2.42 |
| 46 | Parkinson disease 25, autosomal recessive early-onset, with impaired intellectual development | Enrichment | PTPA | 2.42 |
| 47 | Bone marrow failure syndrome 5 | Enrichment | TP53 | 2.42 |
| 48 | Graft-versus-host disease | Enrichment | IL10 | 2.42 |
| 49 | Papilloma of choroid plexus | Enrichment | TP53 | 2.42 |
| 50 | Mirror movements 4 | Enrichment | NTN1 | 2.42 |
| 51 | Basal cell carcinoma 7 | Enrichment | TP53 | 2.42 |
| 52 | Aortic valve disease 3 | Enrichment | ROBO4 | 2.42 |
| 53 | Anaplastic thyroid carcinoma | Enrichment | TP53 | 2.42 |
| 54 | Uveal coloboma-cleft lip and palate-intellectual disability | Enrichment | YAP1 | 2.42 |
| 55 | Hemifacial myohyperplasia | Enrichment | PIK3CA | 2.42 |
| 56 | Capillary malformation of the lower lip, lymphatic malformation of face and neck, asymmetry of face and limbs, and partial/generalized overgrowth | Enrichment | PIK3CA | 2.42 |
| 57 | Ophthalmoplegia, external, with rib and vertebral anomalies | Enrichment | MYF5 | 2.42 |
| 58 | Melorheostosis | Enrichment | MAP2K1 | 2.42 |
| 59 | Leopard syndrome 2 | Enrichment | RAF1 | 2.42 |
| 60 | Cardiofaciocutaneous syndrome 4 | Enrichment | MAP2K2 | 2.42 |
| 61 | Cowden syndrome 6 | Enrichment | AKT1 | 2.42 |
| 62 | Ductal carcinoma in situ | Enrichment | TP53 | 2.42 |
| 63 | Thrombocytopenia 6 | Enrichment | SRC | 2.42 |
| 64 | Ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies | Enrichment | RHOA | 2.42 |
| 65 | Prenatal benign hypophosphatasia | Enrichment | ALPL | 2.42 |
| 66 | Linear hypopigmentation and craniofacial asymmetry with acral, ocular and brain anomalies | Enrichment | RHOA | 2.42 |
| 67 | Trigonitis | Enrichment | RAF1 | 2.42 |
| 68 | Segmental progressive overgrowth syndrome with fibroadipose hyperplasia | Enrichment | PIK3CA | 2.42 |
| 69 | Thyroid gland undifferentiated carcinoma | Enrichment | TP53 | 2.42 |
| 70 | Tufted angioma of skin | Enrichment | KDR | 2.42 |
| 71 | Asphyxia neonatorum | Enrichment | COL1A1 | 2.42 |
| 72 | Small-cell carcinoma of the ovary of hypercalcemic type | Enrichment | TP53 | 2.42 |
| 73 | Hypospadias | Enrichment | PIK3CA | 2.42 |
| 74 | Diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype | Enrichment | TP53 | 2.42 |
| 75 | Choroid plexus cancer | Enrichment | TP53 | 2.42 |
| 76 | Rare venous malformation | Enrichment | PIK3CA | 2.42 |
| 77 | Diaphragmatic eventration | Enrichment | PIK3CA | 2.42 |
| 78 | Pik3ca-related overgrowth spectrum | Enrichment | PIK3CA | 2.42 |
| 79 | Pleomorphic xanthoastrocytoma | Enrichment | TP53 | 2.42 |
| 80 | Rare combined vascular malformation | Enrichment | PIK3CA | 2.42 |
| 81 | Cavernous lymphangioma | Enrichment | PIK3CA | 2.42 |
| 82 | Pik3ca-related overgrowth syndrome | Enrichment | PIK3CA | 2.42 |
| 83 | Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom | Enrichment | RAC1 | 2.42 |
| 84 | Hemihyperplasia-multiple lipomatosis syndrome | Enrichment | PIK3CA | 2.42 |
| 85 | Eccrine angiomatous hamartoma | Enrichment | PIK3CA | 2.42 |
| 86 | Macrodactyly of toe | Enrichment | PIK3CA | 2.42 |
| 87 | Malignant astrocytoma | Enrichment | PTPN11 | 2.42 |
| 88 | Bladder cancer | Enrichment | PIK3CA, TP53 | 2.26 |
| 89 | Prostate cancer | Enrichment | PIK3CA, TP53 | 2.26 |
| 90 | Lung cancer | Enrichment | PIK3CA, PPP2R1B | 2.18 |
| 91 | Ovarian cancer | Enrichment | AKT1, PIK3CA, TP53 | 2.17 |
| 92 | Epiphyseal dysplasia, multiple, 1 | Enrichment | COL1A1 | 2.12 |
| 93 | Adrenocortical carcinoma, hereditary | Enrichment | TP53 | 2.12 |
| 94 | Kyphomelic dysplasia | Enrichment | CCN2 | 2.12 |
| 95 | Dermatofibrosarcoma protuberans | Enrichment | COL1A1 | 2.12 |
| 96 | Cervical cancer | Enrichment | TP53 | 2.12 |
| 97 | Keratosis, seborrheic | Enrichment | PIK3CA | 2.12 |
| 98 | Angioma, tufted | Enrichment | KDR | 2.12 |
| 99 | Noonan syndrome 8 | Enrichment | PIK3CA | 2.12 |
| 100 | Lymphoma, hodgkin, classic | Enrichment | TP53 | 2.12 |
| 101 | Spondyloepimetaphyseal dysplasia, li-shao-li type | Enrichment | CCN2 | 2.12 |
| 102 | Combined osteogenesis imperfecta and ehlers-danlos syndrome 1 | Enrichment | COL1A1 | 2.12 |
| 103 | Intellectual developmental disorder, autosomal dominant 48 | Enrichment | RAC1 | 2.12 |
| 104 | Alpha-thalassemia/impaired intellectual development syndrome, x-linked | Enrichment | ALPL | 2.12 |
| 105 | Epidermolysis bullosa, junctional 5a, intermediate | Enrichment | ITGB4 | 2.12 |
| 106 | Werner syndrome | Enrichment | PTPN11 | 2.12 |
| 107 | Ehlers-danlos syndrome, arthrochalasia type, 2 | Enrichment | COL1A1 | 2.12 |
| 108 | Immunodeficiency 127 | Enrichment | TNF | 2.12 |
| 109 | Rosette-forming glioneuronal tumor | Enrichment | PIK3CA | 2.12 |
| 110 | Congenital fibrosarcoma | Enrichment | TP53 | 2.12 |
| 111 | Stickler syndrome, type ii | Enrichment | COL1A1 | 2.12 |
| 112 | Li-fraumeni syndrome 1 | Enrichment | TP53 | 2.12 |
| 113 | Sarcoma | Enrichment | TP53 | 2.12 |
| 114 | Hypophosphatasia | Enrichment | ALPL | 2.12 |
| 115 | Cervix carcinoma | Enrichment | TP53 | 2.12 |
| 116 | Hodgkin's lymphoma | Enrichment | TP53 | 2.12 |
| 117 | Alpha thalassemia-x-linked intellectual disability syndrome | Enrichment | ALPL | 2.12 |
| 118 | Ehlers-danlos/osteogenesis imperfecta syndrome | Enrichment | COL1A1 | 2.12 |
| 119 | Localized junctional epidermolysis bullosa, non-herlitz type | Enrichment | ITGB4 | 2.12 |
| 120 | Pleomorphic rhabdomyosarcoma | Enrichment | TP53 | 2.12 |
| 121 | Tafro syndrome | Enrichment | MAP2K2 | 2.12 |
| 122 | Systemic lupus erythematosus | Enrichment | IL10, TNF | 2.01 |
| 123 | Hypophosphatasia, infantile | Enrichment | ALPL | 1.94 |
| 124 | Pompe disease, infantile-onset | Enrichment | PIK3CA | 1.94 |
| 125 | Langerhans cell histiocytosis | Enrichment | MAP2K1 | 1.94 |
| 126 | Osteogenic sarcoma | Enrichment | TP53 | 1.94 |
| 127 | Psoriatic arthritis | Enrichment | TNF | 1.94 |
| 128 | Nasopharyngeal carcinoma | Enrichment | TP53 | 1.94 |
| 129 | Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi | Enrichment | PIK3CA | 1.94 |
| 130 | Caffey disease | Enrichment | COL1A1 | 1.94 |
| 131 | Atypical teratoid rhabdoid tumor | Enrichment | TP53 | 1.94 |
| 132 | Anaplastic astrocytoma | Enrichment | TP53 | 1.94 |
| 133 | Squamous cell carcinoma | Enrichment | TP53 | 1.94 |
| 134 | Adenocarcinoma | Enrichment | TP53 | 1.94 |
| 135 | Migraine without aura | Enrichment | TNF | 1.94 |
| 136 | Bone osteosarcoma | Enrichment | TP53 | 1.94 |
| 137 | High bone mass osteogenesis imperfecta | Enrichment | COL1A1 | 1.94 |
| 138 | Tricuspid valve insufficiency | Enrichment | PTPN11 | 1.94 |
| 139 | Keratoacanthoma | Enrichment | PIK3CA | 1.94 |
| 140 | Gastric cancer | Enrichment | PIK3CA, TP53 | 1.93 |
| 141 | Thrombocytopenia | Enrichment | PTPN11, SRC | 1.84 |
| 142 | Mirror movements 1 | Enrichment | NTN1 | 1.82 |
| 143 | Ehlers-danlos syndrome, arthrochalasia type, 1 | Enrichment | COL1A1 | 1.82 |
| 144 | Small cell cancer of the lung | Enrichment | TP53 | 1.82 |
| 145 | Phenylketonuria | Enrichment | COL1A1 | 1.82 |
| 146 | Thyroid cancer, nonmedullary, 1 | Enrichment | TP53 | 1.82 |
| 147 | Neurofibromatosis-noonan syndrome | Enrichment | MAP2K2 | 1.82 |
| 148 | Megalencephaly-capillary malformation-polymicrogyria syndrome | Enrichment | PIK3CA | 1.82 |
| 149 | Chromosome 22q11.2 deletion syndrome, distal | Enrichment | MAPK1 | 1.82 |
| 150 | Epidermolysis bullosa simplex 5c, with pyloric atresia | Enrichment | ITGB4 | 1.82 |
| 151 | Lung sarcomatoid carcinoma | Enrichment | TP53 | 1.82 |
| 152 | Malignant epithelioid hemangioendothelioma | Enrichment | YAP1 | 1.82 |
| 153 | Cerebrovascular disease | Enrichment | PIK3CA | 1.82 |
| 154 | Embryonal rhabdomyosarcoma | Enrichment | TP53 | 1.82 |
| 155 | Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia | Enrichment | PTPN11 | 1.82 |
| 156 | Familial cerebral cavernous malformations | Enrichment | PIK3CA | 1.82 |
| 157 | Osteogenesis imperfecta with normal sclerae, dominant form | Enrichment | COL1A1 | 1.82 |
| 158 | Hypertelorism | Enrichment | COL1A1, PIK3CA | 1.77 |
| 159 | Capillary malformations, congenital | Enrichment | PIK3CA | 1.72 |
| 160 | Epidermolysis bullosa simplex 1c, localized | Enrichment | ITGB4 | 1.72 |
| 161 | Rhabdomyosarcoma 2 | Enrichment | TP53 | 1.72 |
| 162 | Aplasia cutis congenita | Enrichment | ITGB4 | 1.72 |
| 163 | Vascular dementia | Enrichment | TNF | 1.72 |
| 164 | Acute megakaryocytic leukemia | Enrichment | TP53 | 1.72 |
| 165 | Hemimegalencephaly | Enrichment | PIK3CA | 1.72 |
| 166 | Diffuse cutaneous systemic sclerosis | Enrichment | CCN2 | 1.72 |
| 167 | Myeloma, multiple | Enrichment | TP53, YAP1 | 1.71 |
| 168 | Ehlers-danlos syndrome, classic type, 1 | Enrichment | COL1A1 | 1.64 |
| 169 | Klippel-trenaunay-weber syndrome | Enrichment | PIK3CA | 1.64 |
| 170 | Li-fraumeni syndrome | Enrichment | TP53 | 1.64 |
| 171 | Osteogenesis imperfecta, type i | Enrichment | COL1A1 | 1.64 |
| 172 | Cowden syndrome 1 | Enrichment | PIK3CA | 1.64 |
| 173 | Epidermolysis bullosa, junctional 1a, intermediate | Enrichment | ITGB4 | 1.64 |
| 174 | Epidermolysis bullosa, junctional 5b, with pyloric atresia | Enrichment | ITGB4 | 1.64 |
| 175 | Hemangioma, capillary infantile | Enrichment | KDR | 1.64 |
| 176 | Junctional epidermolysis bullosa non-herlitz type | Enrichment | ITGB4 | 1.64 |
| 177 | Keratoconus | Enrichment | COL1A1 | 1.64 |
| 178 | Patent ductus arteriosus | Enrichment | PTPN11 | 1.64 |
| 179 | Adrenocortical carcinoma | Enrichment | TP53 | 1.64 |
| 180 | Limited scleroderma | Enrichment | CCN2 | 1.64 |
| 181 | Il10-related early-onset inflammatory bowel disease | Enrichment | IL10 | 1.64 |
| 182 | Lung squamous cell carcinoma | Enrichment | PIK3CA | 1.64 |
| 183 | Classic ehlers-danlos syndrome | Enrichment | COL1A1 | 1.64 |
| 184 | Esophageal cancer | Enrichment | TP53 | 1.58 |
| 185 | Nevus, epidermal | Enrichment | PIK3CA | 1.58 |
| 186 | Osteogenesis imperfecta, type ii | Enrichment | COL1A1 | 1.58 |
| 187 | Myelofibrosis | Enrichment | SRC | 1.58 |
| 188 | Squamous cell carcinoma, head and neck | Enrichment | TP53 | 1.58 |
| 189 | Essential thrombocythemia | Enrichment | TP53 | 1.58 |
| 190 | Pilomyxoid astrocytoma | Enrichment | RAF1 | 1.58 |
| 191 | Epidermolysis bullosa simplex | Enrichment | ITGB4 | 1.58 |
| 192 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Enrichment | TP53 | 1.58 |
| 193 | Melanocytic nevus syndrome, congenital | Enrichment | RAF1 | 1.52 |
| 194 | Glioma susceptibility 1 | Enrichment | TP53 | 1.52 |
| 195 | Lymphoma, non-hodgkin, familial | Enrichment | TP53 | 1.52 |
| 196 | Rheumatoid arthritis | Enrichment | IL10 | 1.47 |
| 197 | Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies | Enrichment | RAC1 | 1.47 |
| 198 | Junctional epidermolysis bullosa | Enrichment | ITGB4 | 1.47 |
| 199 | Primary hyperaldosteronism | Enrichment | TP53 | 1.47 |
| 200 | Leukemia, chronic lymphocytic | Enrichment | TP53 | 1.42 |
| 201 | Familial colorectal cancer | Enrichment | TP53 | 1.42 |
| 202 | Primary bone dysplasia | Enrichment | COL1A1 | 1.42 |
| 203 | Pectus excavatum | Enrichment | PTPN11 | 1.38 |
| 204 | Asthma | Enrichment | TNF | 1.38 |
| 205 | Myelodysplastic syndrome | Enrichment | TP53 | 1.38 |
| 206 | Osteochondrodysplasia | Enrichment | COL1A1 | 1.38 |
| 207 | Epicanthus | Enrichment | PTPN11 | 1.35 |
| 208 | Juvenile myelomonocytic leukemia | Enrichment | PTPN11 | 1.35 |
| 209 | Congenital long qt syndrome | Enrichment | PTPN11 | 1.35 |
| 210 | Aortic valve disease 1 | Enrichment | ROBO4 | 1.31 |
| 211 | Microphthalmia/coloboma 12 | Enrichment | YAP1 | 1.31 |
| 212 | Diaphragmatic hernia, congenital | Enrichment | ROBO4 | 1.31 |
| 213 | Osteogenesis imperfecta, type iv | Enrichment | COL1A1 | 1.31 |
| 214 | Alzheimer's disease | Enrichment | TNF | 1.31 |
| 215 | Multiple sclerosis | Enrichment | ITGB4 | 1.28 |
| 216 | Aortic aneurysm, familial thoracic 1 | Enrichment | ROBO4 | 1.28 |
| 217 | Lung cancer susceptibility 3 | Enrichment | TP53 | 1.28 |
| 218 | Coloboma of macula | Enrichment | YAP1 | 1.25 |
| 219 | Osteogenesis imperfecta, type iii | Enrichment | COL1A1 | 1.25 |
| 220 | Lynch syndrome | Enrichment | PIK3CA | 1.25 |
| 221 | Rhabdomyosarcoma | Enrichment | TP53 | 1.22 |
| 222 | Gliosarcoma | Enrichment | TP53 | 1.22 |
| 223 | Giant cell glioblastoma | Enrichment | TP53 | 1.20 |
| 224 | Autism spectrum disorder | Enrichment | MAP2K1, PTPN11 | 1.18 |
| 225 | Heart, malformation of | Enrichment | MAPK1 | 1.17 |
| 226 | Patent foramen ovale | Enrichment | PTPN11 | 1.17 |
| 227 | Behcet syndrome | Enrichment | IL10 | 1.15 |
| 228 | Diffuse large b-cell lymphoma | Enrichment | TP53 | 1.15 |
| 229 | Ehlers-danlos syndrome | Enrichment | COL1A1 | 1.15 |
| 230 | Endometrial cancer | Enrichment | PIK3CA | 1.11 |
| 231 | Hepatoblastoma | Enrichment | TP53 | 1.11 |
| 232 | Microcephaly | Enrichment | MAPK1, PTPN11 | 1.09 |
| 233 | Skin disease | Enrichment | ITGB4 | 1.09 |
| 234 | Diamond-blackfan anemia 1 | Enrichment | TP53 | 1.07 |
| 235 | Cardiomyopathy, familial hypertrophic, 1 | Enrichment | RAF1 | 1.05 |
| 236 | Inherited cancer-predisposing syndrome | Enrichment | PTPN11, TP53 | 1.04 |
| 237 | Pancreatic cancer | Enrichment | TP53 | 1.04 |
| 238 | Tetralogy of fallot | Enrichment | KDR | 1.02 |
| 239 | Hydrops fetalis, nonimmune | Enrichment | PTPN11 | 1.02 |
| 240 | Strabismus | Enrichment | PTPN11 | 1.01 |
| 241 | Long qt syndrome 1 | Enrichment | PTPN11 | 0.96 |
| 242 | Non-immune hydrops fetalis | Enrichment | PTPN11 | 0.95 |
| 243 | Familial hypertrophic cardiomyopathy | Enrichment | RAF1 | 0.92 |
| 244 | Left ventricular noncompaction | Enrichment | RAF1 | 0.90 |
| 245 | Diamond-blackfan anemia | Enrichment | TP53 | 0.89 |
| 246 | Leukemia, acute myeloid | Enrichment | TP53 | 0.85 |
| 247 | Hypertrophic cardiomyopathy | Enrichment | PTPN11 | 0.82 |
| 248 | Familial thoracic aortic aneurysm and aortic dissection | Enrichment | COL1A1 | 0.81 |
| 249 | Familial isolated dilated cardiomyopathy | Enrichment | RAF1 | 0.73 |
| 250 | Hereditary breast ovarian cancer syndrome | Enrichment | TP53 | 0.72 |
| 251 | Male infertility with azoospermia or oligozoospermia due to single gene mutation | Enrichment | PTPN11 | 0.71 |
| 252 | Primary ovarian insufficiency | Enrichment | KDR | 0.69 |
| 253 | Dilated cardiomyopathy | Enrichment | RAF1 | 0.58 |